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R E V I E W
Abstract: Patients with type 2 diabetes mellitus (DM) are at increased risk for cardiovascular
disease (CVD), and many patients are inadequately treated for risk factors such as
hyperglycemia, hyperlipidemia, hypertension, and smoking. Providing individualized risk
information in a clear and engaging manner may serve to encourage both patients and their
physicians to intensify risk-reducing behaviors and therapies. This review outlines simple
and effective methods for making CVD risk infomation understandable to persons of all levels
of literacy and mathematical ability. To allow the patient to understand what might happen
and how, personal risk factors should be clearly communicated and the potential consequences
of a CVD event should be presented in a graphic but factual manner. Risk calculation software
can provide CVD risk estimates, and the resulting information can be made understandable
by assigning risk severity (eg, “high”) by comparing clinical parameters with accepted treatment
targets and by comparing the individual’s risk with that of the “average” person. Patients must
also be informed about how they might reduce their CVD risk and be supported in these
efforts. Thoughtful risk communication using these techniques can improve access to health
information for individuals of low literacy, especially when interactive computer technology
is employed. Research is needed to find the best methods for communicating risk in daily
clinical practice.
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Introduction
Cardiovascular disease (CVD), broadly defined as stroke, coronary artery disease,
and peripheral vascular disease is the major cause of morbidity and mortality in
persons with type 2 diabetes mellitus (DM). Up to 80% of persons with diabetes will
develop CVD, and half to two-thirds of all deaths associated with DM are due to
CVD, primarily ischemic heart disease (Meigs et al 1997; Mooradian et al 2003).
Nearly 80% of hospitalizations in the US for chronic complications of diabetes are
attributable to CVD, and the costs associated with macrovascular disease are ten
times greater than those for microvascular disease (Mooradian et al 2003; Vijan et al
2004). While hyperglycemia is the most prominent abnormality in DM, hypertension
and hyperlipidemia are more common and have a greater impact on CVD risk in
people with DM than in nondiabetic individuals (Sowers and Haffner 2002). Despite
the magnitude of this problem and the fact that safe and effective therapies are widely
available, most patients are inadequately treated for CVD risk factors (Phillips et al
2001). While the factors leading to this undertreatment are many and complex, several
commonly encountered physician and patient factors may be amenable to intervention.
From the physician’s perspective, hypertension, hyperlipidemia, cigarette smoking,
and aspirin therapy are often given less attention than hyperglycemia in patients with
diabetes, but may be of equal or greater importance with respect to reducing CVD
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risk (Meigs et al 1997; ADA 2004a, 2004b). Addressing
these multiple comorbidities is challenging for providers
faced with large caseloads and limited time during the
outpatient encounter. In addition, “clinical inertia” among
physicians, ie, recognition of a problem but failure to act, is
well described (Phillips et al 2001; O’Connor 2003; Grant
et al 2004).
From the patient’s perspective, many with DM are
unaware that diabetes itself is a CVD risk factor. A recent
survey found that almost 70% of people with diabetes do
not realize that they are at increased risk of CVD and stroke
(Bairey-Merz et al 2002), and patients often underestimate
their CVD risk (Rothman et al 1999; Strecher et al 1999).
Patients often do not receive sufficient information from
their physicians to allow them to understand their personal
health risk and to participate in their own healthcare (Heisler
et al 2002; Kinnersley et al 2004), and most patients
remember and understand as little as half of what they are
told by their physicians (Rost and Roter 1987; Crane 1997;
Roter 2000). Patients are more likely to translate advice from
their providers into appropriate behavioral changes if they
are made aware of their health status and participate in
treatment decisions (Greenfield et al 1988; Anderson 1995;
Anderson et al 1995).
Even when information is conveyed, many patients have
limited ability to understand risk and risk-reducing therapies
due to low health literacy, defined as the degree to which
individuals have the capacity to obtain, process, and
understand basic health information needed to make
appropriate health decisions. Persons with low health literacy
are unable to fully participate in decisions about their own
health, adhere poorly to prescribed therapies, and are more
likely to have poor glycemic control compared with those
with adequate health literacy (Schillinger et al 2002;
Nielsen-Bohlman et al 2004).
While multifaceted disease management programs have
improved the dissemination of health information to patients,
most primary care physicians work in practice settings
without such programs. Clearly, methods that facilitate
patients’ understanding of their risk, regardless of their
literacy status, and that increase physicians’ ability to impart
health risk information in a busy clinical environment are
urgently needed. This effort should in turn lead to shared
decision making, a process in which the patient’s preferences
and their physician’s knowledge are incorporated into the
therapeutic planning process. Shared decision making has
been shown to improve glycemic control and quality of life
in patients with diabetes (Greenfield et al 1988; Kinnersley
et al 2004).
The elements of CVD risk
communication
“What is a heart attack?”
Effective individualized CVD risk communication can be
constructed around several general principles. Patients want
practical, concise information focused on the identification
of the problem, what specifically they need to do, why it is
in their best interest, and what outcomes they can expect
(Davis et al 2001; Davis, Fredrickson, et al 2002; Davis,
Williams, et al 2002). With respect to CVD risk, patients
want to know: (1) What is CVD? Or what is a heart attack?
(2) Am I at risk of having a heart attack? (3) What can I do
to lower my risk? (Table 1).
Because myocardial infarction (MI) is the most common
and potentially fatal cardiovascular event experienced by
persons with diabetes, it seems appropriate to structure the
discussion of CVD risk around the “risk of having a heart
attack”. However, for many patients, the term “heart attack”
may have little meaning or may be associated with
misperceptions. In order to fully understand the implications
of having an MI, patients must be provided with explicit
information about what exactly might happen and how it
might occur (Avis et al 1989; Gerrard et al 1999; Lipkus
and Hollands 1999; Rothman et al 1999). In this context,
Table 1 Components of comprehensive cardiovascular disease
(CVD) risk communication
1. “What is a heart attack?”
• Graphic illlustration of the atherosclerotic process using simple
language, diagrams, and analogies
• Graphic description of the consequences of a CVD event, eg, pain,
disability, and death as possible consequences of a myocardial
infarction
• Patient testimonials
2. “What is my risk of having a heart attack?”
• Calculation of individual CVD risk (UKPDS Risk Engine)
• Assign risk severity: eg, “high”
• Compare individual risk with “average” risk
• Compare hemoglobin A1c, blood pressure, and cholesterol with
recommended targets
3. “How can I reduce my risk?”
• Overview of therapeutic options
• Shared decision making to develop a treatment plan
• Regular follow-up and feedback regarding the status of CVD risk
factors
NOTE: UKPDS, United Kingdom Prospective Diabetes Study; UKPDS Risk Engine
is available at www.dtu.ox.ac.uk/index.html?maindoc=/ukpds.
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risk perception is affected by the beliefs people have
regarding the causes of the event under discussion (eg, what
causes a heart attack and is it preventable?) and the
consequences of the event (eg, is it potentially fatal?).
To illustrate the causes of increased CVD risk, the link
between CVD risk and specific behavioral or personal
characteristics must be made in clear and easily
understandable terms. This approach has been successful
in rendering overly optimistic perceptions of CVD risk more
accurately (Avis et al 1989; Rothman et al 1999). If a patient
has uncontrolled blood glucose and blood pressure and
smokes, a statement as simple as “smoking, high blood
sugar, and high blood pressure all act together to cause
damage to blood vessels that supply the heart, and this can
cause a heart attack” describes the patient’s characteristics
and associates those characteristics with increased CVD risk.
Many patients simply have not heard or have not understood
this message. The use of widely recognized images and
simple pictures can help to make the disease process easy
to understand, regardless of the literacy level of the patient.
For example, a plumbing pipe becoming progressively
occluded with rust and mineral deposits alongside a diagram
of a narrowed blood vessel provides a relevant, familiar,
and easily understood analogy to describe the process that
leads to heart attack and stroke. These images graphically
reinforce the message about the causes of coronary disease
and MI, and incorporate graphic and allegorical modes of
communication in illustrating how the patient’s personal
characteristics increase their CVD risk.
To illustrate the consequences of a myocardial infarction,
two approaches have been shown to be effective: (1)
highlight the similarities between the patient under
consideration and persons who have experienced an MI;
and (2) graphically illustrate the severity of the consequences
associated with the event (Rothman et al 1999). Both of these
goals might be accomplished by providing patients with a
brief written or audio- or videotaped testimonial from a
hypothetical patient with DM from a similar age and ethnic
background who has experienced an MI. Testimonials have
been shown to be more persuasive than similar information
presented as statistics or straight facts, and the quality of
exemplars has been shown to have a strong effect on one’s
view of the importance of a problem (Rothman et al 1999;
Strecher et al 1999). Testimonials should include a
description of the experience surrounding the acute event
and its long-term effects on the individual’s daily activities.
The serious and potentially fatal nature of an MI should be
clearly communicated to insure that patients are adequately
informed and are appropriately motivated to adopt lifestyle
and therapeutic interventions.
“What is my risk of having a heart
attack?”
The most intuitive way to begin the risk discussion is to
describe the patient’s statistical risk for CVD, eg, “You have
a 30% risk of experiencing a heart attack in the next 10
years”. A variety of risk calculation tools can be accessed
via the Internet, downloaded to PCs or PDAs, and used in
the clinical setting to quickly generate individualized CVD
risk estimates for patients with DM. Although risk
calculators based on the Framingham Heart Study are most
commonly recommended for CVD risk calculation in the
US, diabetes is underrepresented in the Framingham cohort,
making the equations imprecise in estimating CVD risk in
persons with diabetes (Sheridan et al 2003). The UKPDS
Risk Engine (available at www.dtu.ox.ac.uk/index.html?
maindoc=/ukpds) is a validated CVD risk calculator that
appears to be better suited to risk estimation for individuals
with DM (UKPDS Group 2001; Lee et al 2004). The data
upon which the calculator is based are derived from long-
term follow-up of 4050 patients with DM in patients in the
United Kingdom Prospective Diabetes Study (UKPDS), a
20-year trial in which patients of Caucasian, Asian, and Afro-
Caribbean descent were studied to determine the effect of
tight blood glucose and blood pressure control on the risk
of diabetic complications (UKPDS Group 1998). The Risk
Engine will estimate the probability that a cardiovascular
event (fatal or nonfatal MI or sudden death) will happen to
a given patient within a specified time frame, usually 10
years, based on age, gender, race, duration of diabetes,
hemoglobin A1c (A1c), systolic blood pressure (SBP), total
and high-density lipoprotein (HDL) cholesterol, and
smoking status. Although the generalizability of the model
to DM populations other than the UKPDS cohort has not
yet been tested, the Risk Engine provides reasonable
evidence-based CVD risk estimates that can be used to
inform risk communication.
The UKPDS Risk Engine can also be used to
demonstrate the reduction in CVD risk that is possible
through reductions in blood glucose, blood pressure, and
cholesterol levels and through smoking cessation. In a
similar fashion, the Risk Engine can be used to provide
updated CVD risk estimates for patients at each office visit
to demonstrate the reduction in CVD risk that has been
Vascular Health and Risk Management 2005:1(4)304
Roach and Marrero
achieved over time through successful therapeutic
interventions.
Putting risk information in context
While probability-based information regarding personal
CVD risk is a fundamental component of the overall CVD
risk message, many patients do not reliably understand and
interpret numerical probability statistics (probabilities,
percent risk, risk ratios, etc). The understanding of numerical
probability of risk is greatly facilitated when the information
is presented in a context that makes it relevant to the
individual patient (Rothman et al 1999). Several approaches
have been successful in providing this all-important context.
Assigning a specific level of risk to an event (eg, high,
intermediate, low) imparts a meaning to the stated
probability that is readily understandable regardless of
mathematical ability (Rothman et al 1999). For example,
an individual with a 10-year risk of a CVD event of greater
than 20% is considered to be at high risk for the event (NCEP
2001). While “20%” could be variably interpreted by
patients to reflect different degrees of risk, when they are
informed that this represents “high risk”, a clear message is
sent regarding the seriousness of the risk and the need to
act accordingly.
Comparing the patient’s personal risk to “average” risk
has been shown to be effective in communicating
quantitative risk information (Rothman et al 1999). In the
case of CVD risk, individual risk could be compared with
that of an age- and gender-matched individual without
diabetes or other CVD risk factors. For example, a 56 year-
old white man with a 10-year history of DM, a systolic blood
pressure of 163 mmHg, a total cholesterol of 205, and an
HDL cholesterol of 35 has a 35% 10-year risk of having a
CVD event according to the UKPDS Risk Engine. Using
the Framingham-based risk-calculator available at
http://rover2.nhlbi.nih.gov/guidelines/cholesterol/, a man of
the same age without diabetes, hypertension, or hyper-
lipidemia has a 10-year CVD risk of 10%, less than one-
third the risk of the individual with diabetes. This clearly
sends the message that the individual is at greatly increased
risk compared with a similar person without risk factors.
Finally, the provision of an “action standard”, ie, the
level at which action is required or recommended by health
experts, has also been shown to facilitate the communication
of risk information (Avis et al 1989; Gerrard et al 1999;
Lipkus and Hollands 1999; Rothman et al 1999). When the
individual’s blood glucose, blood pressure, and lipid levels
are placed alongside recommended treatment targets, this
serves to illustrate “how abnormal” his or her clinical
parameters are compared with those associated with minimal
risk.
These aspects of the risk message can be most effectively
presented using simple and colorful graphical presentations
designed to make the information easily understood. Bar
charts are well suited for depicting percentages and
proportions, eg, comparing the patient’s risk with average
risk and for depicting the patient’s clinical parameters in
comparison to recommended target ranges as described
above (Lipkus and Hollands 1999). Bar-chart presentations
can be created on pre-printed forms that contain a grid onto
which patients’ clinical information and risk status can be
depicted alongside normal ranges, treatment goals, and risk
estimates for similar healthy persons.
The illustration of absolute risk has been accomplished
using figures that display probabilities in familiar terms
(Lipkus and Hollands 1999). For example, the patient with
a 10-year CVD risk of 35% might be shown a picture of a
chart showing 35 Xs and 65 dots, in which the Xs represent
the proportion of individuals with the same level of CVD
risk. Pre-printed illustrations of 15% risk, 20% risk, etc can
be prepared and patient’s can be provided with the graphic
that most closely reflects their level of risk.
“How can I reduce my risk?”
The final critical element in the risk communication
sequence is to provide patients with information about how
they can work with their healthcare providers to reduce their
risk (Gerrard et al 1999). The understanding of individual
risk and what can be done to decrease risk may present a
unique “teachable moment” in the therapeutic relationship
in which the patient is receptive to the adoption of behavioral
and therapeutic interventions. As suggested by the “stages
of change” model (Ruggiero and Prochaska 1993), providers
should act on the patient’s willingness to accept some
therapeutic changes while respecting decisions not to adopt
others. For example, if the patient is willing to begin
treatment with a cholesterol-lowering medication to address
hyperlipidemia, but is still contemplating the initiation of
insulin therapy, the patient should not be pressured to make
both changes simultaneously. If patients are given the
opportunity to participate in decisions that affect their
healthcare, including the asking of questions and the
expression of concerns, they may be more likely to remain
compliant with prescribed therapies and to report side effects
before discontinuing medications.
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Providing written information to patients about the risk-
reducing benefits of prescribed medications and directing
them to reliable sources of information may facilitate shared
decision making and increase adherence to prescribed
therapies. However, medication nonadherence remains a
very difficult problem to address (Haynes et al 2005). The
most important single effort in this regard may be to maintain
regularly scheduled follow-up, including contacting patients
who miss appointments.
While providing individualized risk information can
promote health, the perception of increased personal risk
may also cause anxiety, especially if: (1) the magnitude of
the risk is very high; (2) uncertainty regarding the risk is
not reduced; (3) no preventive course of action is offered;
(4) people feel unable to adhere to advice for preventive
actions; or (5) if patients lack social support and coping
skills (Pierce et al 2000). These factors should be taken into
account before discussing CVD risk with high-risk patients.
Options for reducing risk should be clearly presented in a
supportive environment that provides continuity of care and
ongoing assistance in attaining treatment goals.
Evidence for the efficacy of risk
communication
Personalized risk communication has been associated with
risk-reducing behavior. Compared with the presentation of
probabilistic information alone (risk expressed in
percentages or proportions), the odds of entering cancer and
cholesterol screening programs was higher when persons
were presented with their categorical risk (ie, high, medium,
or low) and when their own personal risk factors were
outlined (Edwards et al 2004). The efficacy of commun-
icating individualized CVD risk was demonstrated in the
Coronary Health Assessment Study (Lowensteyn et al 1998).
Participants included 253 community-based physicians
randomized into intervention and control groups and 958
of their patients. The intervention group received computer-
generated individualized CVD risk profiles and options for
risk reduction within 10 days of an initial visit, whereas
control patients received this information only if they
returned for a 3-month follow-up visit. The intervention
group had a significantly higher ratio of high-risk/low-risk
patients who returned for a follow-up visit and significantly
greater mean reductions in total and LDL-cholesterol and
predicted 8-year coronary risk. Another study showed
reductions in CHD risk, body mass index, and cholesterol
levels at the 5-year follow-up in intervention groups that
received CHD risk appraisal with or without physician
consultation (Engberg et al 2002).
Knowledge of patients’ CVD risk status has also been
shown to affect physician behavior. When the cardiovascular
risk scores of patients with DM were provided to their
physicians and were categorized as “low” (< 10%),
“moderate” (10%–20%), or “high” (> 20%), physicians
were significantly more likely to prescribe blood pressure
and lipid-lowering drugs than physicians in a control group
who were not provided with risk scores (Hall et al 2003).
Using technology to facilitate risk
communication
The availability of interactive technology presents an
incredibly rich opportunity to create individualized CVD
risk communications for patients with diabetes. Interactive
multimedia presentations can be made mentally and
emotionally engaging through the use of video, graphics,
animation, sound, and text. The presentation of risk
information in this manner has been shown to correct overly
optimistic perceptions of personal risk and is likely to
promote more involvement in the process of learning when
compared with traditional materials (Rothman et al 1999;
Strecher et al 1999).
Interactive technology may be effective in addressing
issues of limited health literacy. Information can be
presented in a manner that does not require literacy or
mathematical ability for understanding, and an
accompanying audio track can provide access to information
for patients who are unable to read. Current technology
permits full patient interaction with automated presentations
with little or no understanding of computer operations.
The availability of an interactive computer-based risk
communication program should improve access to health
information for persons of lower socioeconomic status
(SES). Persons of lower SES have limited access to health
information, an increased prevalence of diabetes and are
more likely to underestimate their health risk compared with
persons of higher SES (Avis et al 1989; Kreuter et al 1995;
Strecher et al 1999). Access to an individualized interactive
risk presentation coupled with physician involvement in
discussing its contents should help to bridge this
“information gap”.
Summary
The effective management of CVD risk factors in patients
with DM is an extraordinarily complex process. Patients
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must be motivated to implement appropriate lifestyle
changes, appropriately self-manage a number of chronic
conditions, and adhere to recommendations for therapy and
follow-up. The successful attainment of treatment goals for
modifiable CVD risk factors requires multidisciplinary
intervention with consideration given to multiple patient,
physician, phamacologic, and environmental factors.
Effective CVD risk communication is merely one
component of a comprehensive risk management effort, but
it plays a central role in the counseling of patients with DM
for whom primary prevention of CVD is the most favorable
outcome. There is evidence that improved patient–physician
communication about CVD risk and risk reduction strategies
can activate both parties toward the intensification of
therapies directed at CVD risk factors.
Individualized risk calculation can be readily perfomed
during outpatient visits using risk calculation software, and
the resulting information can be effectively commnicated
to patients using the approaches outlined above. The risk
message must be presented such that patients understand
the potentially serious consequences of a CVD event and
that they are personally at risk for such an event. Finally,
patients must be given information about options to reduce
their CVD risk. The risk message should be delivered in
conjuction with a clinical encounter with the healthcare
provider so that questions and concerns can be addressed,
and shared decision making can begin. Physicians need not
try to achieve this entire set of communication goals in a
single visit. In fact, risk communication can and should build
upon itself over time and become an integral part of the
patient–physician interaction at each clinic visit.
The availability of interactive computer technology holds
great promise for risk communication. Vivid and engaging
risk messages can be created, and the presentation can be
tailored to individuals of low health literacy. Computer-based
programs may increase the effectiveness and efficiency of
risk communication in that little effort is required of medical
personnel, and patients enter the clinical encounter with
basic information, obviating the need for the physician to
create the entire risk discussion de novo. As technologies
become more widely available and accessible to individuals
across the socioeconomic spectrum, physicians may be able
to provide patients with a portable, interactive individualized
risk presentation in the form of a compact disc that can be
viewed on the patient’s own playback device, and patients
may be able to access this information in their homes via
the Internet. Even if physicians do not have access to
computer-based resources, the risk communication
principles outlined above can be applied to the creation of
simple but vivid print materials that can be constructed in
template form and that incorporate individual patient-based
risk information to be used during the clinical encounter.
While the construction of this risk communication “tool kit”
will require time and effort, its availability should increase
the efficiency of patient counseling for the reduction of CVD
risk, especially if materials can be prepared and compiled
by office personnel and viewed by the patient prior to the
patient–physician encounter.
Further research is needed to optimize risk com-
munication and to incorporate these methods into clinical
practice. The strategies described above for communicating
risk, while based in a theoretical background, are offered
with some caution given the limited amount of data
regarding the optimal methods for constructing the risk
message and the paucity of data regarding the efficacy of
risk communication in altering health-related behavior. A
common and important limitation of studies to date is the
omission of the contextual information necessary for
individuals to fully understand, internalize, and act on risk
information. In addition, studies of the specific effect of
CVD risk communication to patients with diabetes have not
been performed. Therefore, future research should focus
on how to most effectively correct underestimates of risk
on the part of patients and physicians, how to most
effectively communicate probabilistic information to
illustrate magnitude of risk, how to provide a meaningful
context for risk information, and most importantly, how risk
communication affects clinical outcomes, namely the
incidence of cardiovascular events. The availability of
modern interactive computer technology and the powerful
effect of multimedia presentations demand that the efficacy
and feasibility of this mode of risk communication be
evaluated via translational research studies in real-world
settings.
At present, providers of care to persons with diabetes
should utilize all available resources including the principles
of risk communication outlined above, the services of other
health professionals including diabetes educators and
dietitians, and reliable web-based material to facilitate the
communication of health information to patients. Healthcare
providers should use the clinical encounter as an opportunity
to foster patient empowerment and shared decision making,
employing risk communication as one of many critically
important tools in this process. Through this effort, patients
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with DM and their care providers can become partners in
reducing the risk for cardiovascluar disease in this high-
risk population.
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